{"id":45456,"date":"2025-02-03T13:37:44","date_gmt":"2025-02-03T12:37:44","guid":{"rendered":"https:\/\/kapitalpartner.dk\/?p=45456"},"modified":"2025-02-03T13:37:46","modified_gmt":"2025-02-03T12:37:46","slug":"swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend","status":"publish","type":"post","link":"https:\/\/kapitalpartner.dk\/en\/swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend\/","title":{"rendered":"Swedish firm with artificial heart rise 144% – healthcare stocks in upward trend"},"content":{"rendered":"\n

NORDIC | BIOTECH & HEALTHCARE<\/strong> Your insights into listed Danish & Nordic biotech & healthcare stocks.<\/em><\/p>\n\n\n\n

In the past week, the Nordic biotech and healthcare stocks increased by 2.9%, while the Danish rose 1.1%. Most notably, a Swedish company working to create an artificial heart for people in need of a transplant rose 144% following major R&D advancements. Furthermore, Evaxion Biotech announced the closing of an MUSD 10.8 offering and Zealand Pharma got a downgrade by SEB.<\/strong><\/p>\n\n\n\n

9 of the 20 Danish biotech companies had a positive share price development in the past week and 11 companies had a positive share price performance over the past 12 months. Obesity continues to drive the best performances with Gubra, Zealand Pharma, and Pila Pharma having strong LTM performances Gubra is the best performer with 394% over the last twelve months.<\/strong><\/p>\n\n\n\n

\n
Register for the Nordic I Impact newsletter here.<\/strong><\/a><\/div>\n<\/div>\n\n\n\n

<\/p>\n\n\n\n

Danish company news<\/strong><\/p>\n\n\n\n

Acarix AB<\/a><\/strong><\/p>\n\n\n\n

No news in the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Ascendis Pharma<\/a><\/strong><\/p>\n\n\n\n

No news in the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Biosergen<\/a><\/strong><\/p>\n\n\n\n

No news in the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Cessatech<\/a><\/strong><\/p>\n\n\n\n

No news in the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Curasight<\/a><\/strong><\/p>\n\n\n\n

No news in the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

DanCann Pharma<\/a><\/strong><\/p>\n\n\n\n

No news in the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Evaxion Biotech<\/a><\/strong><\/p>\n\n\n\n

Evaxion announces closing of $10.8 million public offering (Link<\/a>)<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

ExpreS2ion<\/a><\/strong><\/p>\n\n\n\n

No news in the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Fluoguide<\/a><\/strong><\/p>\n\n\n\n

No news in the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Genmab<\/a><\/strong><\/p>\n\n\n\n

No news in the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Gubra<\/a><\/strong><\/p>\n\n\n\n

No news in the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Initiator Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

IO Biotech<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Pila Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Saniona<\/a><\/strong><\/p>\n\n\n\n

No news in the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Scandion Oncology<\/a><\/strong><\/p>\n\n\n\n

No news in the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

SynAct Pharma<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

ViroGates<\/a><\/strong><\/p>\n\n\n\n

No news the past wee<\/em>k<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

Zealand Pharma<\/a><\/strong><\/p>\n\n\n\n

SEB lowered their price target from DKK 1,135 to DKK 800.<\/p>\n\n\n\n

Y-mAbs Therapeutic<\/a><\/strong><\/p>\n\n\n\n

Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting (Link<\/a>)<\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/em><\/p>\n\n\n\n

2cureX<\/a><\/strong><\/p>\n\n\n\n

No news the past week<\/p>\n\n\n\n

Share price development \u2013 Danish stocks<\/strong><\/p>\n\n\n\n

On average, the Danish biotech and healthcare stocks delivered a return of 1.1% although Evaxion Biotech<\/a><\/strong> dropped 59% following a public offering at a significant discount. On a more positive note, SynAct Pharma<\/a><\/strong>, ExpreS2ion<\/a><\/strong>, 2cureX<\/a><\/strong>, Pila Pharma<\/a><\/strong>, and DanCann Pharma<\/a><\/strong> saw increases of 10-29%. This increase, however, happened without any company-specific news proving positive momentum. Moreover, Zealand Pharma<\/a><\/strong> dropped 6% following a downgrade from SEB.

Pila Pharma<\/a><\/strong>, Gubra<\/a><\/strong>, and Saniona<\/a><\/strong> are the best performers in the last twelve months with +100% returns each. This comes following a very positive investment environment for companies involved in diabetes and obesity drug development over the past few years. Gubra<\/a><\/strong> is the best performer with a 394% return over the last twelve months. Year-to-date, the average return is 4.2%.<\/p>\n\n\n\n

Investment case for Curasight<\/a><\/strong><\/p>\n\n\n\n

Overview of share price development the past week, year-to-date, and the last twelve month<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Nordic Biotech & Healthcare Developments<\/mark><\/strong><\/p>\n\n\n\n

The <\/span>Kapital Partner Nordic Healthcare Index (KPHC) increased by 2.9% to 66,75 in the past week. The index had a rough start over the past 12 months, then made a comeback followed by another drawback, and now it seems to be on an upward trend. The index has performed better than the C25 Index over the past year, and the return is almost 5%.<\/p>\n\n\n\n

The Nordic healthcare stocks (KPHC) vs. the C25, S30, and KPNGX index the past year<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

The top three best-performing stocks in the past week<\/strong><\/p>\n\n\n\n

SoftOx Solutions<\/a> (229%)<\/strong>  is a Norwegian medical technology company. The company has developed a self-patented solution based on acetic acid for the treatment of chronic wounds in patients. The solution is used to eliminate infections associated with biofilms, which consist of different clusters of bacteria. Part of the drug development takes place in collaboration with other research institutes. The stock rose 180% in the last trading day of the week without any news.<\/p>\n\n\n\n

Scandinavian Real Heart<\/a><\/strong> (144%)<\/strong> main focus is on research and development of heart pumps used among patients with severe heart conditions who are in the queue for transplant. The idea behind the heart pump is to use the product as a transitional solution before a final heart transplant is performed. The company’s stock rose after their Real Heart TAH got approval of humanitarian use device designation by the U.S. Food and Drug Administration. This paves the way for future approvals. Furthermore, the company showed positive results from a 7-day animal study with its Realheart showing adequate cardiac function, automatically adapted to rest and movement, and maintained good blood biochemistry.\u00a0\u00a0<\/p>\n\n\n\n

Chordate Medical Holding<\/strong><\/a> (62%)<\/strong>\u00a0is a medical technology company that has developed, patented,d and CE-marked Ozilia\u00ae Migraine, a neuromodulatory and drug-free treatment technique for chronic migraine and chronic rhinitis. The treatment has proven efficacy according to a clinical study and is marketed in selected markets in the EU and the Middle East. The company published information about their rights issue. Read more here (Link<\/a>).<\/p>\n\n\n\n

Resources: Refinitiv Eikon, Cision, Nordnet & company websites<\/strong><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. In the past week, the Nordic biotech and healthcare stocks increased by 2.9%, while the Danish rose 1.1%. Most notably, a Swedish company working to create an artificial heart for people in need of a transplant rose 144% following major […]<\/p>\n","protected":false},"author":11,"featured_media":43132,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[9,29,165,163],"tags":[],"class_list":["post-45456","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-en-investeringscases","category-investeringscases","category-investment-cases","category-sector-cases"],"acf":[],"yoast_head":"\nSwedish firm with artificial heart rise 144% - healthcare stocks in upward trend | Kapital Partner A\/S<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/kapitalpartner.dk\/en\/swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Swedish firm with artificial heart rise 144% - healthcare stocks in upward trend | Kapital Partner A\/S\" \/>\n<meta property=\"og:description\" content=\"NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. In the past week, the Nordic biotech and healthcare stocks increased by 2.9%, while the Danish rose 1.1%. Most notably, a Swedish company working to create an artificial heart for people in need of a transplant rose 144% following major […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/kapitalpartner.dk\/en\/swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend\/\" \/>\n<meta property=\"og:site_name\" content=\"Kapital Partner A\/S\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/kapitalpartner\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-03T12:37:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-03T12:37:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"724\" \/>\n\t<meta property=\"og:image:height\" content=\"418\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Anders S\u00f8ndergaard\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:site\" content=\"@KapitalPartner\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Anders S\u00f8ndergaard\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend\/\"},\"author\":{\"name\":\"Anders S\u00f8ndergaard\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\"},\"headline\":\"Swedish firm with artificial heart rise 144% – healthcare stocks in upward trend\",\"datePublished\":\"2025-02-03T12:37:44+00:00\",\"dateModified\":\"2025-02-03T12:37:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend\/\"},\"wordCount\":814,\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"articleSection\":[\"All investment Cases\",\"Investeringscases\",\"Investment cases\",\"Sector cases\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend\/\",\"url\":\"https:\/\/kapitalpartner.dk\/en\/swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend\/\",\"name\":\"Swedish firm with artificial heart rise 144% - healthcare stocks in upward trend | Kapital Partner A\/S\",\"isPartOf\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"datePublished\":\"2025-02-03T12:37:44+00:00\",\"dateModified\":\"2025-02-03T12:37:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/kapitalpartner.dk\/en\/swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/kapitalpartner.dk\/en\/swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend\/#primaryimage\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg\",\"width\":724,\"height\":418},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/kapitalpartner.dk\/en\/swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"All investment Cases\",\"item\":\"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/en-investeringscases\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Swedish firm with artificial heart rise 144% – healthcare stocks in upward trend\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/kapitalpartner.dk\/#website\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"name\":\"Kapital Partner A\/S\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/kapitalpartner.dk\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/kapitalpartner.dk\/#organization\",\"name\":\"Kapital Partner A\/S\",\"url\":\"https:\/\/kapitalpartner.dk\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"contentUrl\":\"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png\",\"width\":496,\"height\":432,\"caption\":\"Kapital Partner A\/S\"},\"image\":{\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/kapitalpartner\",\"https:\/\/x.com\/KapitalPartner\",\"https:\/\/www.linkedin.com\/company\/10438322\",\"https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed\",\"name\":\"Anders S\u00f8ndergaard\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g\",\"caption\":\"Anders S\u00f8ndergaard\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Swedish firm with artificial heart rise 144% - healthcare stocks in upward trend | Kapital Partner A\/S","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/kapitalpartner.dk\/en\/swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend\/","og_locale":"en_US","og_type":"article","og_title":"Swedish firm with artificial heart rise 144% - healthcare stocks in upward trend | Kapital Partner A\/S","og_description":"NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks. In the past week, the Nordic biotech and healthcare stocks increased by 2.9%, while the Danish rose 1.1%. Most notably, a Swedish company working to create an artificial heart for people in need of a transplant rose 144% following major […]","og_url":"https:\/\/kapitalpartner.dk\/en\/swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend\/","og_site_name":"Kapital Partner A\/S","article_publisher":"https:\/\/www.facebook.com\/kapitalpartner","article_published_time":"2025-02-03T12:37:44+00:00","article_modified_time":"2025-02-03T12:37:46+00:00","og_image":[{"width":724,"height":418,"url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","type":"image\/jpeg"}],"author":"Anders S\u00f8ndergaard","twitter_card":"summary_large_image","twitter_creator":"@KapitalPartner","twitter_site":"@KapitalPartner","twitter_misc":{"Written by":"Anders S\u00f8ndergaard","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/kapitalpartner.dk\/en\/swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend\/#article","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/en\/swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend\/"},"author":{"name":"Anders S\u00f8ndergaard","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed"},"headline":"Swedish firm with artificial heart rise 144% – healthcare stocks in upward trend","datePublished":"2025-02-03T12:37:44+00:00","dateModified":"2025-02-03T12:37:46+00:00","mainEntityOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend\/"},"wordCount":814,"publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","articleSection":["All investment Cases","Investeringscases","Investment cases","Sector cases"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/kapitalpartner.dk\/en\/swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend\/","url":"https:\/\/kapitalpartner.dk\/en\/swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend\/","name":"Swedish firm with artificial heart rise 144% - healthcare stocks in upward trend | Kapital Partner A\/S","isPartOf":{"@id":"https:\/\/kapitalpartner.dk\/#website"},"primaryImageOfPage":{"@id":"https:\/\/kapitalpartner.dk\/en\/swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend\/#primaryimage"},"image":{"@id":"https:\/\/kapitalpartner.dk\/en\/swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend\/#primaryimage"},"thumbnailUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","datePublished":"2025-02-03T12:37:44+00:00","dateModified":"2025-02-03T12:37:46+00:00","breadcrumb":{"@id":"https:\/\/kapitalpartner.dk\/en\/swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/kapitalpartner.dk\/en\/swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/en\/swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend\/#primaryimage","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2024\/07\/11.jpg","width":724,"height":418},{"@type":"BreadcrumbList","@id":"https:\/\/kapitalpartner.dk\/en\/swedish-firm-with-artificial-heart-rise-144-healthcare-stocks-in-upward-trend\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/kapitalpartner.dk\/en\/"},{"@type":"ListItem","position":2,"name":"All investment Cases","item":"https:\/\/kapitalpartner.dk\/en\/category\/investment-cases\/en-investeringscases\/"},{"@type":"ListItem","position":3,"name":"Swedish firm with artificial heart rise 144% – healthcare stocks in upward trend"}]},{"@type":"WebSite","@id":"https:\/\/kapitalpartner.dk\/#website","url":"https:\/\/kapitalpartner.dk\/","name":"Kapital Partner A\/S","description":"","publisher":{"@id":"https:\/\/kapitalpartner.dk\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/kapitalpartner.dk\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/kapitalpartner.dk\/#organization","name":"Kapital Partner A\/S","url":"https:\/\/kapitalpartner.dk\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/","url":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","contentUrl":"https:\/\/kapitalpartner.dk\/wp-content\/uploads\/2021\/10\/Vandret-logo-PNG.png","width":496,"height":432,"caption":"Kapital Partner A\/S"},"image":{"@id":"https:\/\/kapitalpartner.dk\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/kapitalpartner","https:\/\/x.com\/KapitalPartner","https:\/\/www.linkedin.com\/company\/10438322","https:\/\/www.youtube.com\/channel\/UCODuY5PE_fxmp2nSSsq3l3w"]},{"@type":"Person","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/3225264862e39be271a9aff1c94009ed","name":"Anders S\u00f8ndergaard","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/kapitalpartner.dk\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/27b1d0514d528cdb7505c72f554afadc?s=96&d=mm&r=g","caption":"Anders S\u00f8ndergaard"}}]}},"_links":{"self":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/45456"}],"collection":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/comments?post=45456"}],"version-history":[{"count":1,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/45456\/revisions"}],"predecessor-version":[{"id":45457,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/posts\/45456\/revisions\/45457"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media\/43132"}],"wp:attachment":[{"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/media?parent=45456"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/categories?post=45456"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kapitalpartner.dk\/en\/wp-json\/wp\/v2\/tags?post=45456"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}